[의학신문·일간보사=김영주 기자]inno.N is working with Voronoi, a new drug research and development company, to develop global anticancer drugs. The anticancer drug line is a next-generation line with only two products worldwide, and is a promising market that is expected to grow to about 2 trillion won in 2026. Inno.N took the development of global anticancer drugs as its core growth engine, and recently introduced a new drug substance from Voronoi. With the aim of entering global clinical trials in 2022, it plans to grow this substance into one of the leading new drug pipelines to compete in the global market.
 |
| inno.N BI (left), Voronoi CI (right) |
‘VRN061782′, a new anticancer drug introduced by inno.N, is a family of’selective RET (Rearranged during transfection) kinase inhibitors’. It is a principle that inhibits the activity of this gene when the’RET gene’ among the kinase enzymes, which is a signaling substance in the body, causes a mutation or when cancer occurs due to binding to another gene.
Inno.N plans to develop a customized target anticancer drug that selectively targets only cancer cells with the same in vivo indicator (biomarker) regardless of the location of the cancer, including lung cancer and thyroid cancer with RET gene fusion or mutation. The goal is to develop the best new anticancer drug (Best in class) in the line with differentiation such as anticancer effect, overcoming resistance, and safety.
VRN061782 is characterized by a higher response to drug resistance than the existing competitor drugs of the same class in non-clinical animal studies. In addition, excellent cardiovascular safety was confirmed by selecting and attacking only specific genes.
Inno.N CEO Seok-Hee Kang said, “Our goal is to quickly enter the global anticancer drug market through the synergy of Voronoi’s excellent new drug candidate search and research capabilities and inno.N’s new drug development capabilities.” We plan to secure pipelines in various disease fields with global competitiveness.”
Voronoi CEO Dae-Kwon Kim said, “We are pleased to establish a partnership with inno.N, which has abundant clinical development capabilities. Through this partnership, we have demonstrated the excellence of Voronois®, a discovery platform that Voronoi has built.” He added.
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>